Quoin Pharmaceuticals Ltd (QNRX) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Quoin Pharmaceuticals Ltd. is grappling with a serious business risk that could significantly impact its financial stability and investor relations. On April 29, 2024, the company received a deficiency notice from Nasdaq due to its failure to meet the Minimum Bid Price Requirement over a span of 31 consecutive business days. Quoin Pharmaceuticals has until October 28, 2024, to regain compliance or face potential delisting. Such an outcome could severely limit market liquidity, reduce the company’s ability to raise capital, and erode investor confidence.
The average QNRX stock price target is $7.00, implying 805.97% upside potential.
To learn more about Quoin Pharmaceuticals Ltd’s risk factors, click here.
